GlaxoSmithKline PLC

GSK-N

NYSE:GSK

41.01
0.21 (0.51%)
GlaxoSmithKline plc is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest ...
More at Wikipedia

Analysis and Opinions about GSK-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
March 20, 2007
Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.
Show full opinionHide full opinion
Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.
BUY
BUY
November 30, 2006
Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.
Show full opinionHide full opinion
GlaxoSmithKline PLC (GSK-N)
November 30, 2006
Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.
DON'T BUY
DON'T BUY
November 8, 2006
A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.
Show full opinionHide full opinion
A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.
PAST TOP PICK
PAST TOP PICK
August 17, 2006
(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.
Show full opinionHide full opinion
(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.
TOP PICK
TOP PICK
May 8, 2006
Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.
Show full opinionHide full opinion
Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.
BUY
BUY
March 20, 2006
5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.
Show full opinionHide full opinion
5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.
BUY
BUY
December 6, 2005
The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.
Show full opinionHide full opinion
The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.
BUY
BUY
July 15, 2004
Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.
Show full opinionHide full opinion
Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.
TOP PICK
TOP PICK
March 11, 2004
Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.
Show full opinionHide full opinion
Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.
WEAK BUY
WEAK BUY
September 3, 2003
They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.
Show full opinionHide full opinion
GlaxoSmithKline PLC (GSK-N)
September 3, 2003
They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.
BUY
BUY
October 15, 2002
Likes, but prefers Johnson & Johnson.
Show full opinionHide full opinion
Likes, but prefers Johnson & Johnson.
BUY
BUY
June 25, 2002
Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%.
Show full opinionHide full opinion
Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%.
BUY
BUY
March 8, 2002
Prefers over US pharmaceuticals. Better situated globally.
Show full opinionHide full opinion
Prefers over US pharmaceuticals. Better situated globally.
TOP PICK
TOP PICK
January 28, 2002
Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget.
Show full opinionHide full opinion
Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget.
BUY
BUY
August 7, 2001
Has a new drug, competing with Prozac. Also into biotechs, making good diversification.
Show full opinionHide full opinion
Has a new drug, competing with Prozac. Also into biotechs, making good diversification.
BUY
BUY
June 26, 2001
Good merger. A safe holding.
Show full opinionHide full opinion
Good merger. A safe holding.
PAST TOP PICK
PAST TOP PICK
March 27, 2001
(Was a top pick on Oct 11 - Down 6%) but still likes it.
Show full opinionHide full opinion
(Was a top pick on Oct 11 - Down 6%) but still likes it.
BUY
BUY
March 27, 2001
Bullet proof portfolio-large caps (40%)
Show full opinionHide full opinion
Bullet proof portfolio-large caps (40%)
BUY
BUY
February 14, 2001
A good merger making them the largest pharmaceutical
Show full opinionHide full opinion
GlaxoSmithKline PLC (GSK-N)
February 14, 2001
A good merger making them the largest pharmaceutical
Showing 61 to 79 of 79 entries